tetano
Editor, Senior Moderator
Neurobiol Dis
. 2023 May 11;182:106147.
doi: 10.1016/j.nbd.2023.106147. Online ahead of print. Uncovering a neurological protein signature for severe COVID-19
Omar El-Agnaf[SUP] 1 [/SUP], Ilham Bensmail[SUP] 2 [/SUP], Maryam A Y Al-Nesf[SUP] 3 [/SUP], James Flynn[SUP] 4 [/SUP], Mark Taylor[SUP] 5 [/SUP], Nour K Majbour[SUP] 6 [/SUP], Ilham Y Abdi[SUP] 6 [/SUP], Nishant N Vaikath[SUP] 6 [/SUP], Abdulaziz Farooq[SUP] 7 [/SUP], Praveen B Vemulapalli[SUP] 8 [/SUP], Frank Schmidt[SUP] 8 [/SUP], Khalid Ouararhni[SUP] 9 [/SUP], Heba H Al-Siddiqi[SUP] 10 [/SUP], Abdelilah Arredouani[SUP] 10 [/SUP], Patrick Wijten[SUP] 11 [/SUP], Mohammed Al-Maadheed[SUP] 12 [/SUP], Vidya Mohamed-Ali[SUP] 12 [/SUP], Julie Decock[SUP] 13 [/SUP], Houari B Abdesselem[SUP] 14 [/SUP]
Affiliations
Coronavirus disease of 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has sparked a global pandemic with severe complications and high morbidity rate. Neurological symptoms in COVID-19 patients, and neurological sequelae post COVID-19 recovery have been extensively reported. Yet, neurological molecular signature and signaling pathways that are affected in the central nervous system (CNS) of COVID-19 severe patients remain still unknown and need to be identified. Plasma samples from 49 severe COVID-19 patients, 50 mild COVID-19 patients, and 40 healthy controls were subjected to Olink proteomics analysis of 184 CNS-enriched proteins. By using a multi-approach bioinformatics analysis, we identified a 34-neurological protein signature for COVID-19 severity and unveiled dysregulated neurological pathways in severe cases. Here, we identified a new neurological protein signature for severe COVID-19 that was validated in different independent cohorts using blood and postmortem brain samples and shown to correlate with neurological diseases and pharmacological drugs. This protein signature could potentially aid the development of prognostic and diagnostic tools for neurological complications in post-COVID-19 convalescent patients with long term neurological sequelae.
Keywords: Neurological complications; Olink proteomics; Protein signature; Severe COVID-19.
. 2023 May 11;182:106147.
doi: 10.1016/j.nbd.2023.106147. Online ahead of print. Uncovering a neurological protein signature for severe COVID-19
Omar El-Agnaf[SUP] 1 [/SUP], Ilham Bensmail[SUP] 2 [/SUP], Maryam A Y Al-Nesf[SUP] 3 [/SUP], James Flynn[SUP] 4 [/SUP], Mark Taylor[SUP] 5 [/SUP], Nour K Majbour[SUP] 6 [/SUP], Ilham Y Abdi[SUP] 6 [/SUP], Nishant N Vaikath[SUP] 6 [/SUP], Abdulaziz Farooq[SUP] 7 [/SUP], Praveen B Vemulapalli[SUP] 8 [/SUP], Frank Schmidt[SUP] 8 [/SUP], Khalid Ouararhni[SUP] 9 [/SUP], Heba H Al-Siddiqi[SUP] 10 [/SUP], Abdelilah Arredouani[SUP] 10 [/SUP], Patrick Wijten[SUP] 11 [/SUP], Mohammed Al-Maadheed[SUP] 12 [/SUP], Vidya Mohamed-Ali[SUP] 12 [/SUP], Julie Decock[SUP] 13 [/SUP], Houari B Abdesselem[SUP] 14 [/SUP]
Affiliations
- PMID: 37178811
- PMCID: PMC10174474
- DOI: 10.1016/j.nbd.2023.106147
Coronavirus disease of 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has sparked a global pandemic with severe complications and high morbidity rate. Neurological symptoms in COVID-19 patients, and neurological sequelae post COVID-19 recovery have been extensively reported. Yet, neurological molecular signature and signaling pathways that are affected in the central nervous system (CNS) of COVID-19 severe patients remain still unknown and need to be identified. Plasma samples from 49 severe COVID-19 patients, 50 mild COVID-19 patients, and 40 healthy controls were subjected to Olink proteomics analysis of 184 CNS-enriched proteins. By using a multi-approach bioinformatics analysis, we identified a 34-neurological protein signature for COVID-19 severity and unveiled dysregulated neurological pathways in severe cases. Here, we identified a new neurological protein signature for severe COVID-19 that was validated in different independent cohorts using blood and postmortem brain samples and shown to correlate with neurological diseases and pharmacological drugs. This protein signature could potentially aid the development of prognostic and diagnostic tools for neurological complications in post-COVID-19 convalescent patients with long term neurological sequelae.
Keywords: Neurological complications; Olink proteomics; Protein signature; Severe COVID-19.